Search Results
Your search for The A matches 33001 pages
Showing 22501 - 22550Richard Pazdur, MD, Named Acting Director of the FDA Oncology Center of Excellence
U.S. Food and Drug Administration (FDA) Commissioner Robert Califf, MD, issued the following statement today regarding the appointment of the Acting Director of the FDA Oncology Center of Excellence. “The FDA is honored to be an integral part of the Vice President’s National Cancer...
FDA Approves Sofosbuvir/Velpatasvir for Treatment of Chronic Hepatitis C Virus Infection
On June 28, the U.S. Food and Drug Administration (FDA) approved a fixed-dose combination of sofosbuvir, 400 mg, plus velpatasvir, 100 mg (Epclusa) to treat adult patients with chronic hepatitis C virus (HCV) either with or without cirrhosis. For patients with moderate to severe cirrhosis...
ASCO Outlines Opposition to Medicare Part B Demo for Senate Finance Hearing
ASCO voiced its strong opposition to the proposed Medicare Part B demonstration project in comments submitted on June 28 for the U.S. Senate Finance Committee hearing, “Examining the Proposed Medicare Part B Drug Demonstration.” ASCO underscored the urgent need to advance a fairer...
Study Finds Addition of High-Dose Cytarabine to Immunochemotherapy Before Transplant Improves Outcomes in Younger Patients With MCL
The phase III European MCL Younger trial has shown that adding high-dose cytarabine to immunochemotherapy prior to autologous stem cell transplantation (ASCT) increased the time to treatment failure among patients with mantle cell lymphoma (MCL) aged ≤ 65 years. The results were reported by...
No Overall Advantage to Adding Pertuzumab to Chemotherapy in Platinum-Resistant Ovarian Cancer, but Subgroup May Benefit
According to the European phase III PENELOPE trial reported in the Journal of Clinical Oncology, Kurzeder et al found that adding pertuzumab (Perjeta) to investigator’s choice of chemotherapy did not improve progression-free survival in women with low-HER3 mRNA–expressing...
Ipilimumab Combined With Antigen-Specific Cytotoxic T Lymphocytes May Be of Benefit in Metastatic Melanoma
In a study reported in the Journal of Clinical Oncology by Chapuis et al, concurrent use of cytotoxic T lymphocyte (CTL) antigen-4 (CTLA-4) blockade with ipilimumab (Yervoy) and adoptively transferred antigen-specific CTLs produced enduring responses in patients with stage IV melanoma. Study...
CAP, IASLC, and AMP Seek Public Comments on Revised Lung Cancer Molecular Testing Guideline
The College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association for Molecular Pathology (AMP) announced today the open comment period for the revised evidence-based guideline, “Molecular Testing Guideline for Selection of...
Influence of Microbiota of Breast Tissue on the Development of Cancers
Bacteria that have the potential to abet breast cancer are present in the breasts of cancer patients, while beneficial bacteria are more abundant in healthy breasts, where they may actually be protecting women from cancer, according to Gregor Reid, PhD, of the Lawson Health Research Institute, and...
Nivolumab Receives FDA Breakthrough Therapy Designation for Advanced/Metastatic Urothelial Carcinoma
Bristol-Myers Squibb Company announced June 27 that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to nivolumab (Opdivo) for the potential indication of unresectable locally advanced or metastatic urothelial carcinoma that has progressed on or after a...
Reduced-Intensity Transplantation With Haploidentical Related Donors vs HLA-Matched Sibling Donors in Patients With Lymphoma
In an analysis of the observational data base of the Center for International Blood and Marrow Transplant Research reported in the Journal of Clinical Oncology, Ghosh et al found that lymphoma patients undergoing reduced-intensity conditioning had similar outcomes with related-donor haploidentical...
Is Nivolumab Active in Recurrent Small Cell Lung Cancer?
In the phase I/II CheckMate 032 study, nivolumab (Opdivo) alone and with ipilimumab (Yervoy) demonstrated activity in patients with small cell lung cancer (SCLC) progressing after at least one previous platinum regimen, as reported in The Lancet Oncology by Antonia et al. Study Details In the...
Scenes From ASCO 2016
1. General views. Photo © ASCO/Matt Herp 2016; 2. Amanda Redig, MD, PhD, recipient of the 2016 Women Who Conquer Cancer Young Investigator Award. Photo © ASCO/Danny Morton 2016; 3. Himisha Beltran, MD, speaks during Precision Medicine in Advanced Prostate Cancer: Understanding Genomics,...
Lawrence O. Gostin, JD, LLD, Appointed to National Cancer Advisory Board
President Barack Obama has tapped Lawrence O. Gostin, JD, LLD, Georgetown University Professor and Faculty Director of the O’Neill Institute for National and Global Health Law at Georgetown Law, to serve as a member of the National Cancer Advisory Board (NCAB). He will serve a 6-year term. The 18 ...
I Was Not Shown Compassion by My Medical Team
At my last screening mammogram in 2015, nothing seemed out of the ordinary. The technician took the usual four x-rays of my breasts, and I was told I could leave. So it was especially shocking to get a phone call from the radiologist a week later telling me that I had to come back for an additional ...
Precision Medicine Clinical Trial for Metastatic Pancreatic Cancer Now Open at Multiple Sites
The first clinical trial to compare standard-of-care chemotherapy with molecularly tailored therapy (also known as precision medicine) for metastatic pancreatic cancer is now enrolling patients at multiple sites around the country. Patients who have been treated with one round of chemotherapy for...
Four-Biomarker Panel Identified for Chronic Graft-vs-Host Disease
In a study reported in the Journal of Clinical Oncology, Jeffrey Yu, MD, of the Indiana University School of Medicine, Indianapolis, and colleagues identified a four-biomarker panel that was predictive of chronic graft-vs-host disease after allogeneic hematopoietic cell transplantation. Discovery...
Increased Risk of Gallbladder Cancer May Be Associated With Consuming Large Amounts of Sweetened Beverages
A large prospective Swedish study reported by Susanna C. Larsson, PhD, of the Unit of Nutritional Epidemiology at the Institute of Environmental Medicine at Karolinska Institutet in Stockholm, Sweden, and colleagues found a 2.2-fold increased risk of gallbladder cancer in people who consumed two or ...
Adding Adjuvant Oxaliplatin to Fluoropyrimidine May Be of Benefit in Deficient Mismatch Repair Colon Cancer
In a French retrospective study reported by David Tougeron, MD, PhD, of Poitiers University Hospital, Poitiers, France, and colleagues in the Journal of the National Cancer Institute, the addition of adjuvant oxaliplatin to fluoropyrimidine treatment improved disease-free survival in patients with...
Retroviral Replicating Vector That Delivers Cytosine Deaminase to Cancer Cells Active in Recurrent Glioblastoma
A phase I study by Timothy F. Cloughesy, MD, Director of the Neuro-Oncology Program at the UCLA Jonsson Comprehensive Cancer Center, and colleagues published in Science Translational Medicine investigated the effectiveness of vocimagene amiretrorepvec (Toca 511), an experimental nonlytic,...
AMA Announces Board of Trustees for 2016–2017
The American Medical Association (AMA) has introduced the 21 members of its Board of Trustees for the coming year, following elections held during the Annual Meeting of the AMA House of Delegates. Andrew W. Gurman, MD, an orthopedic hand surgeon, was sworn in as the 171st President of the AMA. In...
Use Questions From Patients to Help Them Make Informed Treatment Decisions
Recent reports about treatment options for patients with ductal carcinoma in situ, and the ensuing debate and comments played out in the media, may prompt increased questions from patients. A review summarizing data about these treatment options concluded that surgery and radiation therapy “remain...
Surgery and Radiation Therapy Remain Standard of Care for Managing Ductal Carcinoma in Situ
A review of more than 50 studies (many randomized controlled trials) concluded that surgery and radiation therapy “remain standard-of-care treatment options” in the management of ductal carcinoma in situ.1 The review continues the widely reported discussion on managing ductal carcinoma in situ,...
Taubman Prize Jointly Awarded to Suzanne L. Topalian, MD, and Jedd D. Wolchok, MD, PhD, for Groundbreaking Work in Cancer Immunotherapy
Two clinician-scientists whose groundbreaking work has shown how the human body’s own immune system can fend off cancer will share the 2016 $100,000 Taubman Prize for Excellence in Translational Medical Science, the University of Michigan’s A. Alfred Taubman Medical Research Institute announced....
Something Happened
Over the years, my patients have been my most important teachers. I’ve learned so much from them about human nature and the resilience of the human spirit. When my time came to pass through the fire and confront the same challenges they and their families face so bravely and with such compassion, ...
Ohio State Names Timothy Pawlik, MD, MPH, PhD, Chair of Surgery and Chair for Cancer Research
The Ohio State University Wexner Medical Center has appointed a nationally recognized surgeon and liver cancer expert to lead its surgical and surgical oncology programs. Timothy Pawlik, MD, MPH, PhD, will be the Chair of the Medical Center’s Department of Surgery, as well as The Urban Meyer III...
Black Cohosh
Scientific Name: Cimicifuga racemosa Common Names: Black snakeroot, rattlesnake root, squawroot, bugbane, bugwort Brand Names: Remifemin, Menofem, Klimadynon Overview A perennial plant native to the eastern United States and Canada, black cohosh root was used by Native Americans to treat colds,...
Inside Knowledge From a Cancer Survivor
Curtis Pesmen is a well-regarded writer who has authored six books of nonfiction as well as numerous articles for publications such as Esquire and The New York Times. He also has served as founding editor of LIVESTRONG Quarterly and often speaks and writes on patient advocacy. Shortly after...
A Journalist’s Cancer Saga
Readers of the recently published memoir A Series of Catastrophes & Miracles: A True Story of Love, Science, and Cancer find out that the book has a happy ending on the cover page of chapter 1. Spoiler: I lived, writes the author, Mary Elizabeth Williams, an acclaimed journalist with a list...
An Exotic Journey Into Immunotherapy
In his new book, Sharks Get Cancer, Mole Rats Don’t: How Animals Could Hold the Key to Unlocking Cancer Immunity in Humans, James S. Welsh, MD, examines a wide array of animal and human biologic phenomena, searching for clues that might help us unlock the full power of the human immune system....
Newly Launched Genomic Data Commons to Facilitate Data and Clinical Information Sharing
The Genomic Data Commons (GDC), a unified data system that promotes sharing of genomic and clinical data among researchers, was launched on June 6 with a visit from Vice President Joe Biden to the operations center at the University of Chicago. An initiative of the National Cancer Institute (NCI),...
St. Jude Is First U.S. Children’s Hospital to Earn CAP ISO15189 Accreditation
The St. Jude Department of Pathology has received accreditation to the ISO15189 standard under the College of American Pathologists (CAP) 15189SM Accreditation Program. St. Jude is the first children’s hospital in the nation to be accredited under this program. The accreditation is based on the...
St. Jude Children’s Research Hospital Names Michael Dyer, PhD, Chair of Developmental Neurobiology
St. Jude Children’s Research Hospital has named Michael Dyer, PhD, Chair of the Department of Developmental Neurobiology. “A true visionary in his field, Dr. Dyer is a remarkable scientist who has worked tirelessly to unravel some of the long-held mysteries of childhood cancer,” said James R....
Peter S. Conti, MD, PhD, Receives SNMMI 2016 Paul C. Aebersold Award for Outstanding Achievement in Basic Nuclear Medicine Science
Peter S. Conti, MD, PhD, Professor of Radiology, Pharmaceutical Sciences, and Biomedical Engineering, and Director of the Molecular Imaging Center at the Keck School of Medicine at the University of Southern California, has been named the 2016 recipient of the prestigious Paul C. Aebersold Award....
Moonshot Program for … Compassion
A 65-year-old patient with widely metastatic pancreatic cancer was emergently transferred to our facility in the early hours of the morning with free air suggestive of a perforated viscus. The patient is from a small town several hundred miles away from our academic center, which can be quite...
Clinical Trials Actively Recruiting Patients With Ocular Cancer
Phase 0 Study Title: Use of Definity® Contrast Agent for Ultrasound of Intraocular Tumors Study Type: Interventional/single-group assignment Study Sponsor and Collaborators: Emory University Purpose: To determine if microbubbles may be used as a contrast agent to help image tumors in the eye. In...
VUMC Designated as a Lung Cancer Screening Center
Vanderbilt University Medical Center (VUMC) has been designated a Lung Cancer Screening Center by the American College of Radiology (ACR). The ACR Lung Cancer Screening Center designation is a voluntary program that recognizes facilities that have committed to practice safe, effective diagnostic...
Katherine L. Nathanson, MD, Receives AACR’s Frohlich Visiting Professorship
Katherine L. Nathanson, MD, Professor of Medicine in the Division of Translational Medicine and Human Genetics at the Perelman School of Medicine of the University of Pennsylvania, has received the 2015 Frohlich Visiting Professorship through the American Association for Cancer Research (AACR)....
Vanguard Practices Support Sharing Big Data With CancerLinQ™
CancerLinQ LLC, recently announced that it has completed agreements with 36 vanguard oncology practices from around the country to begin implementing the tool. According to physicians at the vanguard practices, gaining access to the experience of oncology practices across the country motivated...
The ASCO Research Community Forum Is Expanding
In 2010, ASCO established the Community Research Forum to support clinical investigators and community-based research sites. Building on the Forum’s success in providing solutions for community-based research programs and the cancer research community at large, ASCO has decided to expand the Forum...
Initiative to Modernize Eligibility Criteria for Clinical Trials Launched
ASCO and Friends of Cancer Research (Friends) have launched a collaborative effort to modernize eligibility criteria to promote greater patient participation in cancer clinical trials. Although it is important for defining the population under study and ensuring patient safety, overly strict...
Meet Thomas G. Roberts, Jr, MD
Thomas G. Roberts, Jr, MD, is Managing Member at Farallon Capital Management, LLC and Chair of the Conquer Cancer Foundation of ASCO Board of Directors and Executive Committee. What led you to oncology prior to your career in finance? TGR: As an intern at Massachusetts General Hospital, I was...
Clinical Conversations: Attendee Questions From the Cancer Survivorship Symposium
The inaugural Cancer Survivorship Symposium, held in January 2016, drew more than 800 attendees across the cancer-care spectrum—far exceeding the goal of 500 attendees. As a way to continue the discussion from the meeting, several faculty members responded to questions from General Sessions 5 and...
ASCO Endows Young Investigator Award in Honor of Society Founder Jane Cooke Wright, MD
For the first time in ASCO’s history, the Society has endowed its own Young Investigator Award (YIA), illustrating its continued commitment to investing in the future of cancer research. Ongoing support of this kind will ensure that the Conquer Cancer Foundation (CCF), ASCO’s philanthropic arm, is...
Erratum
In the June 10 issue of The ASCO Post, the article "Anti–PD-1 Inhibitor Gains Foothold in Merkel Cell Carcinoma," a photo labeled Paul Nghiem, MD, PhD, is incorrect. The photo that was printed is Paul Nguyen, MD, of the Dana-Farber Cancer Institute. A photo of Dr. Nghiem is shown here. Dr. Nghiem ...
Geriatric Oncology in Asia: The Dawn of a New Era in Cancer Care
Asia is currently experiencing an unprecedented rate of growth in its aging population. This “silver tsunami” has translated into a burgeoning number of older patients with cancer, as cancer is a disease of aging. However, unlike their Western counterparts, elderly patients with cancer in Asia are ...
Geriatric Patients With Cancer and the Problem of Polypharmacy
Older patients with cancer generally have multiple comorbidities, with each often requiring separate medications. Studies have shown that polypharmacy and inappropriate drug use are prevalent among older cancer patients, leading to an enormous amount of preventable adverse events, many requiring...
Pembrolizumab in Triple-Negative Breast Cancer: Emerging New Treatment Modality
Lajos Pusztai, MD, DPhil, Professor of Medicine, Chief of Breast Medical Oncology and Co-Director of Cancer Genetics Research Program at Yale Cancer Center, New Haven, Connecticut, commented on KEYNOTE-012. He remarked that the overall response rate of 18.5% to the single agent is similar to...
Anti–PD-1 Treatment With Pembrolizumab in Gastric/Gastroesophageal Junction Cancers: Who Is Likely to Respond?
Immune checkpoint inhibitors have emerged as one of the most promising new areas of drug development in oncology. Broad activity has been observed for these agents across a spectrum of hematologic malignancies and solid tumors. As reviewed in this issue of The ASCO Post, Muro and colleagues now...
Nivolumab or Ipilimumab Treatment May Increase Risk of Developing Autoimmune Joint and Tissue Disease
Case reports on 13 patients with cancer suggest that patients taking the immunotherapeutics ipilimumab (Yervoy) and nivolumab (Opdivo) may be at higher-than-normal risk of developing autoimmune joint and tissue diseases, including inflammatory arthritis, according to a preliminary study by Johns...
Hypofractionated Radiation Found Equivalent to Conventionally Fractionated Regimen in Early-Stage Breast Cancer
Early-stage breast cancer patients receiving a shorter course of whole-breast irradiation with higher radiation doses per fraction reported equivalent cosmetic, functional, and pain outcomes over time as those receiving a longer, lower-dose per fraction course of treatment, according to researchers ...
